GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PeptiDream Inc (OTCPK:PPTDF) » Definitions » Net Income Including Noncontrolling Interests

PPTDF (PeptiDream) Net Income Including Noncontrolling Interests : $92.9 Mil (TTM As of Mar. 2025)


View and export this data going back to 2014. Start your Free Trial

What is PeptiDream Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

PeptiDream's Net Income Including Noncontrolling Interests for the three months ended in Mar. 2025 was $-6.9 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2025 was $92.9 Mil.

PeptiDream Net Income Including Noncontrolling Interests Historical Data

The historical data trend for PeptiDream's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PeptiDream Net Income Including Noncontrolling Interests Chart

PeptiDream Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial Premium Member Only Premium Member Only 42.86 22.61 55.99 21.09 97.62

PeptiDream Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.62 118.89 -2.13 -16.94 -6.93

PeptiDream Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $92.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PeptiDream Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of PeptiDream's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

PeptiDream Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PeptiDream Inc (OTCPK:PPTDF) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
TSE:4592 TSE:2160 TSE:4974 TSE:4565 TSE:219A TSE:4894 TSE:4593 TSE:4575 TSE:7774 TSE:4563 VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
4587:Japan
Address
1-2-10, Nihonbashi, Chuo-ku, Toyo Building, 6th Floor, Tokyo, JPN, 103-0027
Website
http://www.peptidream.com
PeptiDream Inc is a biopharmaceutical company, engaged in the research and development of new pharmaceutical candidates. It discovers constrained peptides, small molecules, and peptide-drug conjugate therapeutics using its Peptide Discovery Platform System. The company aspires to be a leader in drug discovery and development to address unmet medical needs and improve the quality of life of patients worldwide.